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Ab stra ct
In tro duc tion: Ca re ful mo ni to ri ng of drug con cen tra tion (the ra peu tic drug mo ni to ri ng, TDM) is es sen tial for a lar ge num ber of dru gs. The aim of this 
stu dy was to eva lua te ana lyti cal per for man ce of Ab bo tt AxSYM ana lyzer for the ra peu tic drug mo ni to ri ng of theop hylli ne, car ba ma ze pi ne, phe no-
bar bi tal and val proic acid.
Ma te ria ls and met ho ds: For the pur po se of ana lyti cal va li da tion fol lowi ng pa ra me te rs we re de ter mi ned for all ana lytes: inac cu ra cy (bias), wit hi-
n-run and be twee n-run im pre ci sion and mea su re me nt un cer tain ty. Ad di tio nal ly, con cen tra tion of val proic acid was com pa red with the pre vious ly 
used ana lyti cal system (TDx FLx Ab bo tt ana lyzer) for 30 pa tien ts’ sam ples.
Re sul ts: Inac cu ra cy re sul ts (bias) we re as fol lows: for theop hylli ne from –3.66% to –5.84%; for car ba ma ze pi ne –0.46% to 1.00%; for phe no bar bi tal 
–1.83% to –8.08% and for val proic acid from –1.01% to –5.65%. The hig he st coeB   cie nt of va ria tion (CV) for wit hin run im pre ci sion was ob ser ved 
for phe no bar bi tal (7.07%) and the lowe st for theop hylli ne (2.71%). The hig he st CV for be tween run im pre ci sion was ob ser ved for car ba ma ze pi ne 
(4.73%) and the lowe st for theop hylli ne (2.94%). The hig he st mea su re me nt un cer tain ty was ob ser ved for phe no bar bi tal as say (21.7%) and the 
lowe st for car ba ma ze pi ne (10.7%).
Pas si ng-Bab lo ck reg res sion ana lysis of val proic acid com pa ri son on two ana lyze rs showed sta tis ti cal ly sig ni I  ca nt, but cli ni cal ly in sig ni I  ca nt de via-
tion in slo pe of the reg res sion equa tion (b = 1.121; 95% CI = 1.028–1.197); howe ver the Cu sum li nea ri ty te st pro ved that the re was a li near re la tion-
ship be tween two met ho ds.
Con clu sion: In con clu sion, ana lyti cal va li da tion ful I l led all pre vious ly es tab lis hed cri te ria and cou ld be im ple men ted in a rou ti ne la bo ra to ry wo rk.
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In tro duc tion
Ca re ful mo ni to ri ng of drug con cen tra tion (the ra-
peu tic drug mo ni to ri ng, TDM) is es sen tial for a lar-
ge num ber of dru gs. Dru gs wi th nar row the ra peu-
tic ran ge can ea si ly ac hie ve eit her too hi gh or too 
low se rum con cen tra tion. Ele va ted drug con cen-
tra tion in the blood stream can cau se si de e@ ec ts 
wi th se rious and so me ti mes even fa tal con sequen-
ces. On the con tra ry, drug con cen tra tion be low 
the the ra peu tic ran ge can lead to ina dequa te res-
pon se to the ra py.
Val proic acid, phe no bar bi tal and car ba ma ze pi ne 
are an tie pi lep tic dru gs (AE Ds) that have been used 
for treat me nt of sei zu res in epi lep sy and ot her di-
sor de rs (1–3). The se dru gs requi re con sta nt mo ni-
to ri ng to main tain the con cen tra tion wit hin the 
the ra peu tic ran ge. Al thou gh, no vel se co nd- (4) and 
thi r d-ge ne ra tion (5) an tie pi lep ti cs ha ve now days 
been prescri bed mo re frequen tly, the se dru gs sti ll 
re main treat me nt of choi ce for so me types of pe-
diat ric epi lep sy (6).
Theop hylli ne is a bron cho dia la ta tor wi th a nar row 
the ra peu tic ran ge and lar ge in te rin di vi dual va ria-
bi li ty in phar ma co ki ne ti cs. Hi gh se rum con cen tra-
tio ns of theop hylli ne are as so cia ted wi th se rious 
ad ver se reac tio ns. Al thou gh its use has been dec li-
ni ng in the pa st two de ca des, it is sti ll used as an 
ad di tio nal treat me nt drug in the as thma tic acu te 
pha se in chil dren (7,8).
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In our la bo ra to ry, TDM is per for med usi ng W uo res-
cen ce po la ri za tion im mu noas say (FPIA) tec hno lo-
gy on TDx FLx Ab bo tt ana lyzer (Ab bo tt La bo ra to-
ries, Ab bo tt Pa rk, IL, USA). For met ho ds ba sed on 
an ti ge n-an ti bo dy reac tion a lar ge va ria bi li ty be-
tween di@ e re nt types/generations of rea gen ts can 
be ob ser ved (9). Our expe rien ces ha ve shown that 
even in ter chan geab le ana lytic syste ms of the sa-
me ki nd of ana lyze rs can show dis cre pan cies in a 
re su lt and shou ld be ca re ful ly mo ni to red and com-
pa red (10). Fur ther mo re, as a la bo ra to ry accre di ted 
ac cor di ng to ISO 15189 stan da rd, we are ob li ged to 
per fo rm an ana lyti cal va li da tion of ea ch new rea-
ge nt/analyzer prior to met hod ve ri _  ca tion and in-
tro duc tion to rou ti ne la bo ra to ry wo rk (11).
Aim of this pa per was to des cri be the re sul ts of 
ana lyti cal va li da tion of Ab bo tt AxSYM ana lyzer for 
the ra peu tic drug mo ni to ri ng of val proic acid, phe-
no bar bi tal, car ba ma ze pi ne and theop hylli ne.
Ma te ria ls and met ho ds
Met ho ds
This stu dy was perfor med at Uni ver si ty De par tme-
nt of Che mis try, Ses tre mi los r dni ce Uni ver si ty Hos-
pi tal in No vem ber 2009. Con cen tra tion of the ra-
peu tic dru gs theop hylli ne, car ba ma ze pi ne, phe-
no bar bi tal and val proic acid was de ter mi ned on 
AxSYM ana lyzer (Ab bo tt La bo ra to ries, Ab bo tt Pa-
rk, IL, USA) usi ng ori gi nal ma nu fac tu rer’s rea gen ts 
and pro ce du res. For the com pa ra bi li ty stu dy, val-
proic acid was de ter mi ned on Ab bo tt TDx FLx ana-
lyzer (Ab bo tt La bo ra to ries, Ab bo tt Pa rk, IL, USA). 
All ana lytes we re de ter mi ned by W uo res cen ce po-
la ri za tion im mu noas say (FPIA) tec hno lo gy.
The ra peu tic in ter va ls used in our la bo ra to ry we re 
as fol lows: for theop hylli ne 28–83 µmol/L; for car-
ba ma ze pi ne 17–42 µmol/L; for phe no bar bi tal 65–
172 µmol/L and for val proic acid 347–693 µmol/L.
Ana lytic eva lua tion
Inac cu ra cy
Inac cu ra cy was de ter mi ned usi ng three con cen tra-
tion le ve ls of the com mer cial con trol sam ples. Lot 
num be rs for con trol sam ples we re: 69072Q100 for 
Theop hylli ne II Con trol; 76484Q100 for Car ba ma-
ze pi ne Con trol; 69641Q100 for Phe no bar bi tal Con-
trol and 76480Q100 Val proic Acid Con trol (Abbo tt 
La bo ra to ries, Ab bo tt Pa rk, IL, USA). Ea ch sam ple 
was ana lyzed three ti mes; ave ra ge re su lt was com-
pa red to ma nu fac tu re rs dec la red va lue and the 
bias was cal cu la ted. Ac cep tan ce cri te ria for ea ch 
ana lyte we re es tab lis hed ac cor di ng to the CLIA 
Pro _  cien cy Tes ti ng cri te ria (12).
Wit hin run im pre ci sion (re pea ta bi li ty)
Re pea ta bi li ty was de ter mi ned usi ng se ra of two 
pa tie nts for ea ch ana lyte (sam ples A and B). Ea ch 
sam ple was ana lyzed ten ti mes in a bat ch ana-
lysis. Coei   cie nt of va ria tion (CV) was cal cu la ted 
and com pa red to the ac cep tan ce cri te ria dec la-
red by the ma nu fac tu rer for ap prop ria te con cen-
tra tion le ve ls, as we ll as to cri te ria pro po sed by 
Gui de li nes of the Ger man Fe de ral Me di cal Coun-
cil (13).
Be tween ru n im pre ci sion (in ter me dia te pre ci sion)
In ter me dia te pre ci sion was de ter mi ned usi ng pool 
of three pa tien ts’ sam ples for ea ch ana lyte. The se 
sam ples we re re mai ni ng se ra from the rou ti ne 
drug mo ni to ri ng ana lysis. Sam ples we re mixed 
and aliquo ted in ten se pa ra te tu bes and fro zen at 
–20 °C. Du ri ng the 15-days pe riod, on ce a day at 
di@ e re nt ti me of the rou ti ne wo rk one sam ple was 
thawed and ana lyzed. Coei   cie nt of va ria tion was 
cal cu la ted and com pa red to the ac cep tan ce cri te-
ria dec la red by the ma nu fac tu rer, as we ll as to cri-
te ria pro po sed by Gui de li nes of the Ger man Fe de-
ral Me di cal Coun cil (13).
Mea su re me nt un cer tain ty
Mea su re me nt un cer tain ty (U) was cal cu la ted for all 
tes ts ac cor di ng to the for mu la (14):




bias +  u
2
bias  innaccuracy .
Whe re:
Uca lib ra tor is a ca lib ra tor mea su re me nt un cer tain ty 
as dec la red by the ma nu fac tu rer.
Uim pre ci sion is an un cer tain ty cau sed by im pre ci-
sion. In our ca se, coei   cie nt of va ria tion for be-
tween run im pre ci sion was used.
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Ubias is an un cer tain ty cau sed by inac cu ra cy. In our 
ca se, bias of the com mer cial con trol sam ple wi th 
the va lue clo se st to the sam ple for the be tween 
run im pre ci sion was used.
Ubias inac cu ra cy is an un cer tain ty cau sed by inac cu-
ra cy when cal cu la ti ng bias. It is cal cu la ted usi ng 




Ubias inaccuracy = 
ux
x
   × 100
Met hod com pa ri son
Met hod com pa ri son was do ne usi ng re mai ni ng 
se ra for the pa tien ts re fer red to la bo ra to ry for val-
proic acid de ter mi na tion. For 30 pa tien ts, val proic 
acid was de ter mi ned on the Ab bo tt TDx FLx ana-
lyzer as a pa rt of a rou ti ne wor kup and than im me-
dia te ly ana lyzed at AxSYM Ab bo tt ana lyzer.
Sta tis ti cal ana lysis
Da ta on the com mer cial con trol sam ples are pre-
sen ted as arit hme tic mean and the bias to the ma-
nu fac tu re rs’ dec la red va lue was cal cu la ted. For the 
im pre ci sion ana lysis, mi ni mum, maxi mum, arit-
hme tic mean, stan da rd de via tion and coei   cie nt 
of va ria tion we re cal cu la ted. For the com pa ri son 
ana lysis, val proic acid con cen tra tion is pre sen ted 
as mean ± stan da rd de via tion and Pas si ng-Bab lo-
ck reg res sion ana lysis (alo ng wi th Cu sum li nea ri ty 
te st) was per for med. Sta tis ti cal ana lysis was per-
for med wi th MedCalc® sof twa re (Med Ca lc 10.1.3.1., 
Fra nk Schoo nja ns, Ma ria ker ke, Bel gium).
Re sul ts
Inac cu ra cy for all ana lytes was in ac cor dan ce wi th 
the pre vious ly es tab lis hed cri te ria (Tab le 1). The 
hig he st bias was ob ser ved for the Phenobar bi tal 
Me dium Con trol (–8.08%), but it was al so wit hin 
the ac cep tan ce cri te ria.
Da ta on wit hin run im pre ci sion (re pea ta bi li ty) are 
pre sen ted in tab le 2. The hig he st coei   cie nt of va-
ria tion was ob ser ved for the phe no bar bi tal as say 
(7.07%) and the lowe st for the theop hylli ne (2.71%). 
Tab le 3 shows the da ta on between run im pre ci-
sion (in ter me dia te pre ci sion). The hig he st coei  -
cie nt of va ria tion was ob ser ved for the car ba ma ze-
pi ne (4.73%) and the lowe st for the theop hylli ne 
(2.94%). No ne of the ob tai ned coei   cien ts of va ria-
tion met the cri te ria dec la red by the ma nu fac tu rer. 
Howe ver, all va lues ful _ l led the requi re men ts as 
pro po sed by the Ger man Fe de ral Me di cal Coun cil 
(13).
Com mer cial con trol sam ple Dec la red va lue
(μmol/L)
Mean mea su red va lue
(μmol/L)
Bias Ac cep tan ce cri te ria
Theop hylli ne II Con trol Low 38.85 37.00 –4.75%
± 25%Me dium 66.60 62.71 –5.84%
Hi gh 144.30 139.02 –3.66%
Car ba ma ze pi ne Con trol Low 12.69 12.82 1.00%
± 25%Me dium 25.38 25.23 –0.58%
Hi gh 67.68 67.37 –0.46%
Phe no bar bi tal Con trol Low 64.65 62.45 –3.40%
± 20%Me dium 129.30 118.85 –8.08%
Hi gh 215.50 211.57 –1.83%
Val proic Acid Con trol Low 259.88 245.19 –5.65%
± 25%Me dium 519.75 493.33 –5.08%
Hi gh 866.25 857.53 –1.01%
TAB LE 1. Re sul ts of inac cu ra cy analysis.
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Mea su re me nt un cer tain ty was cal cu la ted for all 
ana lytes ac cor di ng to the pre vious ly des cri bed for-
mu la (14) (Tab le 4). The hig he st un cer tain ty was ob-
ser ved for pheno bar bi tal (21.7%), whi ch was ex pec-
ted, sin ce the hig he st inac cu ra cy and coei   cie nt of 
va ria tion we re al so ob ser ved for the sa me ana lyte.
Theop hylli ne
(μmol/L)
Car ba ma ze pi ne 
(μmol/L)




Sam ple (N = 10) A B A B A B A B
MIN 19 62 25 35 99 171 474 768
MAX 21 68 28 39 119 209 567 870
Xsr 19.9 65.4 26.0 37.4 107.7 182.3 521.2 814.4
SD 0.7 1.8 0.9 1.2 5.6 12.9 29.7 34.8
CV (%) 3.43 2.71 3.34 3.12 5.22 7.07 5.69 4.27
Ac cep tan ce cri te ria for CV 
(ma nu fac tu rer) (%) 2.00 1.70 2.60 2.60 3.32 4.75 4.10 3.50
Ac cep tan ce cri te ria for CV 
(li te ra tu re) (2) (%) 13.0 12.0 10.0 11.5




Car ba ma ze pi ne 
(μmol/L)
N = 10






MIN 25 31 88 562
MAX 27 37 97 619
Xsr 26.0 34.5 92.0 587.1
SD 0.8 1.6 3.4 17.3
CV (%) 3.11 4.73 3.66 2.94
Ac cep tan ce cri te ria for CV 
(ma nu fac tu rer) (%) 0.8 1.1 0.19 0.5
Ac cep tan ce cri te ria for CV 
(li te ra tu re) (2) (%) 13.0 12.0 10.0 11.5
TAB LE 3. Re sul ts on be tween run im pre ci sion ana lysis.
Ana lyte
Uca lib ra tor
(%)








Theop hylli ne 1.4 3.1 4.8 1.4 12.1
Car ba ma ze pi ne 1.4 4.7 0.6 2.1 10.7
Phe no bar bi tal 4.9 3.7 8.1 3.8 21.7
Val proic Acid 1.4 2.9 5.1 1.6 12.5
TAB LE 4. Mea su re me nt un cer tain ty re sul ts.
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Com pa ri son of val proic acid con cen tra tion de ter-
mi na tion on two analyze rs is pre sen ted in tab le 5 
and _  gu re 1. Pas si ng-Bab lo ck reg res sion ana lysis 
showed sta tis ti cal ly sig ni _  ca nt, but cli ni cal ly in sig-
ni _  ca nt de via tion in slo pe of the reg res sion equa-
tion (b = 1.121; 95% CI = 1.028–1.197); howe ver the 
Cusum li nea ri ty te st pro ved that the re was a li near 
re la tion ship be tween two met ho ds.
Dis cus sion
The aim of this stu dy was to eva lua te TDM as says 
on Ab bo tt AxSYM ana lyzer. Ove ra ll, all ob tai ned 
pa ra me te rs we re sa tis fac to ry and ful _ l led pre vious-
ly es tab lis hed cri te ria.
Inac cu ra cy stu dy showed the hig he st bias for phe-
no bar bi tal as say (–8.08%), for the me dium con trol 
con cen tra tion le vel of 129.30 (99.56–159.04) μmol/L, 
sur pri sin gly, sin ce one cou ld expe ct the hig he st er-
ror for the hig he st con cen tra tion va lues. Howe ver, 
this con cen tra tion ran ge is wit hin the re fe ren ce 
ran ge of phe no bar bi tal mo ni to ri ng (65–172 µmol/L) 
and not near the cri ti cal va lue that is as so cia ted wi-
th the in crea sed ri sk of si de e@ ec ts (> 220 µmol/L). 
Due to that, we be lie ve that inac cu ra cy coul dn’t 
ha ve hi gh cli ni cal im pa ct. Never the less, the pro po-
sed ac cep tan ce cri te ria for toxi co lo gy TDM by CLIA 
Pro _  cien cy Tes ti ng cri te ria are mu ch hig her than 
tho se ob tai ned in our eva lua tion (12).
Im pre ci sion ana lysis showed si mi lar CVs in wit hin 
run and be tween run stu dies. Mo reo ver, for so me 
as says (val proic acid and phe no bar bi tal) CVs ob tai-
ned in be tween run ana lysis we re even smal ler than 
tho se in the bat ch ana lysis, sug ges ti ng a great sta-
bi li ty of per for man ce for the se as says. Howe ver, 
neit her of ob tai ned coei   cien ts of va ria tion ful _ l-
led the cri te ria es tab lis hed by the ma nu fac tu rer. It 
cou ld be expec ted, sin ce the ma nu fac tu rer de _ -
ned tho se CVs usi ng com mer cial con trol sam ples 
as the ma te rial of the ana lysis. In our stu dy, we 
Val proic Acid TDx
(μmol/L)
Val proic Acid 
AxSYM (μmol/L)
reg res sion 
equa tion
95% con B  den ce in ter val P (Cu sum 
li nea ri ty te st)
in ter ce pt, a slo pe, b
N=30 382 ± 157 401 ± 173 y = –25.161 + 1.121x –48.318–1.535 1.028–1.197 P > 0.10
TAB LE 5. Pas si ng-Bab lo ck reg res sion ana lysis.
FI GU RE 1. Com pa ri son of val proic acid con cen tra tion de ter mi na tion on two ana lyze rs (Ab bo tt TDx and AxSYM).
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wan ted to si mu la te the con di tio ns of rou ti ne la bo-
ra to ry wo rk and we ha ve de ter mi ned our im pre ci-
sion usi ng pa tien ts’ sam ples. Our ob tai ned CVs al-
so ful _ l led ac cep tan ce cri te ria es tab lis hed by the 
Ger man Fe de ral Me di cal Coun cil (13).
We ha ve de ci ded to expa nd our ana lyti cal va li da-
tion by pre sen ti ng re sul ts of mea su re me nt un cer-
tain ty. Mea su re me nt un cer tain ty en com pas ses all 
com po nen ts tat can in W uen ce on the re su lt: syste-
ma tic and ran dom er ror pa ra me te rs of the as say 
and er ro rs ob tai ned by un cer tain ty of ca lib ra to rs 
and it’s es ti ma te (15). Mea su re me nt un cer tain ty is 
sti ll not ful ly im ple men ted in a stan da rd la bo ra to-
ry eva lua tio ns, sin ce one cou ld be puz zled by “hig-
h” num be rs usual ly ob tai ned in this ana lysis. Sin ce 
the mea su re me nt un cer tain ty is a pro per ty of an 
ea ch mea su re me nt re su lt, we are ob li ged to gi ve 
an es ti ma te of ran ge whe re our re su lt is po si tio-
ned in or der to en su re to the use rs of our ana lysis a 
true in ter pre ta tion of ob tai ned va lue. Mea su re me-
nt un cer tain ties for our va li da tion we re al so sa tis-
fac to ry (~10–20%), sin ce we cou ld expe ct the se va-
lues for im mu noc he mis try ana lysis (16).
Sin ce all tes ted ana lytes uti li ze the sa me tec hno lo-
gy (FPIA), we ha ve de ci ded to ma ke the com pa ri-
son be tween two ana lytic syste ms on ly for one 
rep re sen ta ti ve ana lyte – val proic acid. Com pa ra bi-
li ty stu dy al so showed a sa tis fac to ry con cor dan ce 
be tween val proic acid de ter mi na tio ns on two ana-
lyze rs. When we ha ve to rep la ce an ana lytic sys-
tem in a rou ti ne la bo ra to ry prac ti ce, it is ve ry im-
por ta nt not to ha ve a con sta nt de via tion from the 
re su lt. In that ca se, a re fe ren ce ran ge shou ld be 
mo di _ ed in or der to main tain a cor re ct in ter pre ta-
tion of la bo ra to ry re su lt and en su re pro per TDM 
for the pa tie nt. The sma ll de via tion in slo pe of the 
reg res sion li ne that we ha ve ob ser ved in our ana-
lysis was in the hi gh con cen tra tion ran ge (Fi gu re 1) 
and that sma ll di@ e ren ce has no cli ni cal im pli ca-
tion on in ter pre ta tion of the re su lt. Our con clu sio-
ns shou ld be con _ r med on lar ger num ber of sam-
ples, sin ce the low num ber of val proic acid de ter-
mi na tio ns used in our com pa ra bi li ty stu dy is a li-
mi ta tion to our wo rk.
In con clu sion, our ana lyti cal va li da tion ful _ l led all 
pre vious ly es tab lis hed cri te ria and cou ld be im ple-
men ted in a rou ti ne la bo ra to ry wo rk. We cou ld 
rep la ce our exis ti ng system wi th a new ana lyzer 
wit hout ha vi ng in W uen ce on the re su lt of the ra-
peu tic drug mo ni to ri ng for pa tien ts.
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Ana li tič ka va li da ci ja te ra pij skog pra će nja kon cen tra ci je li je ka na ana li za to ru 
AxSYM tvr tke Ab bo tt
Sa že tak
Uvod: Paž lji vo te ra pij sko pra će nje kon cen tra ci je li je ka (en gl. the ra peu tic drug mo ni to ri ng, TDM) od ključ ne je važ nos ti za ve lik broj li je ko va. Cilj 
ovog is tra ži va nja bio je od re di ti ana li tič ke zna čaj ke ana li za to ra AxSYM tvr tke Ab bo tt u te ra pij skom pra će nju kon cen tra ci je teo I  li na, kar ba ma ze-
pi na, fe no bar bi ta la i val proič ne ki se li ne.
Ma te ri ja li i me to de: U svr hu ana li tič ke va li da ci je za sve ana li te od re đe ni su slje de ći pa ra met ri: ne toč no st (en gl. bias), nep re ciz no st u se ri ji i iz 
da na u dan (en gl. wit hi n-run and be twee n-run im pre ci sion) i mjer na ne si gur no st (en gl. mea su re me nt un cer tain ty). Do dat no je za 30 uzo ra ka na či-
nje na us po red ba od re đi va nja kon cen tra ci je val proič ne ki se li ne s pret hod no ko riš tenim sus tavom (ana li za tor TDx FLx tvr tke Ab bo tt).
Re zul ta ti: Re zul ta ti za ne toč no st (pog reš ka) bi li su za teo I  lin od –3,66% do –5,84%; za kar ba ma ze pin –0,46%–1,00%; za fe no bar bi tal 
–1,83%–(–8,08%) i za val proič nu ki se li nu od –1,01% do –5,65%. Naj vi ši koe I  ci je nt va ri ja ci je (en gl. coeB   cie nt of va ria tion, CV) za nep re ciz no st 
unu tar se ri je do bi ven je za fe no bar bi tal (7,07%), a naj ni ži za teoI  lin (2,71%). Naj vi ši CV za nep re ciz no st iz se ri je u se ri ju iz ra ču nat je za kar ba ma-
ze pin (4,73%), a naj ni ži za teo I  lin (2,94%). Naj vi ša mjer na ne si gur no st do bi ve na je za fe no bar bi tal (21,7)%, a naj ni ža za kar ba ma ze pin (10,7%).
Re zul tat us po red be re zul tata kon cen tra ci je val proične ki se li ne na dva ana li za to ra reg re sij skom ana lizom po Pas si ng-Bab loc ku po ka zao je sta tis-
tič ki zna čaj no, ali kli nič ki nez nat no od stu pa nje u na gi bu reg re sij ske jed nad žbe (b = 1,121; 95% CI = 1,028–1,197); me đu tim Cu sum te st li near-
nos ti po ka zao je da pos to ji li near na po ve za no st iz me đu dvi ju me to da.
Zak lju čak: Mo že mo zak lju či ti da je ana li tič ka va li da ci ja is pu ni la sve pret hod no ut vr đe ne kri te ri je te da se ana li za tor mo že uk lju či ti u ru tin ski rad 
la bo ra to ri ja.
Ključ ne ri je či: ana li tič ka va li da ci ja; mjer na ne si gur no st; val proič na ki se li na; fe no bar bi tal; kar ba ma ze pin; teo I  lin
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